FLKS stock forecast
Our latest prediction for Flex Pharma, Inc.'s stock price was made on the Oct. 16, 2018 when the stock price was at 0.69$.
In the short term (2weeks), FLKS's stock price should underperform the market by -0.31%. During that period the price should oscillate between -13.91% and +32.62%.
In the medium term (3months), FLKS's stock price should outperform the market by 11.57%. During that period the price should oscillate between -25.84% and +77.00%.Get email alerts
Create a solid portfolio with FLKS
About Flex Pharma, Inc.
Flex Pharma, Inc. operates as a clinical-stage biotechnology company. It operates through the Consumer Operations and Drug Development segments. The Consumer Operations segment includes HOTSHOT product and consumer operations. The Drug Development segment engages in the development of innovative and proprietary drug products to treat muscle cramps and spasms associated with severe neurological conditions. The company was founded by Rod MacKinnon, Bruce Bean, Christoph Westphal, Rich Aldrich, Michelle Dipp, and Jennifer M. Cermak in February 2014 and is headquartered in Boston, MA.
At the moment the company generates 1M USD in revenues.
On its last earning announcement, the company reported a loss of -1.56$ per share.
The book value per share is 0.74$
Three months stock forecastOct. 16, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|